Business Description
HAEMATO AG, founded in 1993, is a listed pharmaceutical company. The company is listed on the Entry Standard (Open Market) of the Frankfurt Stock Exchange and is based in Schönefeld.
HAEMATO AG is active in the pharmaceutical sector. The focus of business activities is on the growth markets for off-patent and patent-protected drugs and the manufacture of medications. The focus is on therapies for cancer, HIV and other chronic diseases.
Company Information
| First trading day | 10.05.1993 |
| Accounting standard | HGB / IFRS |
| Run | terminated as of 31.12.2017 |
| Management Board | Daniel Kracht, Executive Director |
| Supervisory Board | Andrea Grosse, Chairwoman of the Supervisory Board Prof. Dr. Dr. Sabine Meck, Deputy chairwoman of the Supervisory Board Dr. Marion Braun, Member of the Supervisory Board |
Information on Trade Data
| Specialist | ODDO SEYDLER BANK AG, Schillerstraße 27, 60313 Frankfurt am Main |
| Designated Sponsor | ICF Kursmakler AG, Kaiserstraße 1, D-60311 Frankfurt am Main |
| Listing Partner | ICF Kursmakler AG, Kaiserstraße 1, D-60311 Frankfurt am Main |
| DSP | ICF Kursmakler AG, Kaiserstraße 1, D-60311 Frankfurt am Main |
| Number of shares | 2.286.715 |
| Stock capital | 2.286.715,00 € |
| Freefloat | 51,8 % |
| Shareholder structure | M1 Kliniken AG 48,2 % (as of: 1.07.2020) |
HAEMATO AG
HAEMATO AG
Lilienthalstraße 5c
12529 Schönefeld
Germany
Phone: +49-30 897 30 86 70
Telefax: +49-30 897 30 86 79
E-Mail: info@haemato.ag
HAEMATO Group